ATE395919T1 - Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen - Google Patents

Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen

Info

Publication number
ATE395919T1
ATE395919T1 AT04803177T AT04803177T ATE395919T1 AT E395919 T1 ATE395919 T1 AT E395919T1 AT 04803177 T AT04803177 T AT 04803177T AT 04803177 T AT04803177 T AT 04803177T AT E395919 T1 ATE395919 T1 AT E395919T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
heart disease
selective estrogens
hypertension heart
Prior art date
Application number
AT04803177T
Other languages
English (en)
Inventor
Christa Hegele-Hartung
Karl-Heinrich Fritzemeier
Olaf Peters
Theo Pelzer
Ludwig Neyses
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE395919T1 publication Critical patent/ATE395919T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT04803177T 2003-11-26 2004-11-16 Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen ATE395919T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090406 2003-11-26

Publications (1)

Publication Number Publication Date
ATE395919T1 true ATE395919T1 (de) 2008-06-15

Family

ID=34626396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04803177T ATE395919T1 (de) 2003-11-26 2004-11-16 Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen

Country Status (16)

Country Link
US (1) US20050148560A1 (de)
EP (1) EP1689410B1 (de)
JP (1) JP2007512279A (de)
AR (1) AR046672A1 (de)
AT (1) ATE395919T1 (de)
DE (1) DE602004014020D1 (de)
DK (1) DK1689410T3 (de)
ES (1) ES2307064T3 (de)
GT (1) GT200400241A (de)
PA (1) PA8618401A1 (de)
PE (1) PE20050665A1 (de)
PL (1) PL1689410T3 (de)
PT (1) PT1689410E (de)
TW (1) TW200530263A (de)
UY (1) UY28630A1 (de)
WO (1) WO2005051401A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
EP2143432A1 (de) * 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-Alpha-Estratrien-Derivate als ER-Beta-selektive Liganden zur Prävention und Behandlung von Darmkrebs
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK14632002A3 (sk) * 2000-04-12 2003-03-04 Schering Aktiengesellschaft Substituované estratriény a ich použitie ako selektívne účinných estrogénov
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
GB2374412A (en) * 2001-04-11 2002-10-16 Karobio Ab Hypertension treatment and assay
US7414043B2 (en) * 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Also Published As

Publication number Publication date
WO2005051401A2 (en) 2005-06-09
DE602004014020D1 (de) 2008-07-03
DK1689410T3 (da) 2008-09-08
US20050148560A1 (en) 2005-07-07
EP1689410B1 (de) 2008-05-21
AR046672A1 (es) 2005-12-14
WO2005051401A3 (en) 2005-09-01
UY28630A1 (es) 2005-06-30
TW200530263A (en) 2005-09-16
PL1689410T3 (pl) 2008-10-31
PE20050665A1 (es) 2005-11-02
EP1689410A2 (de) 2006-08-16
GT200400241A (es) 2005-10-31
PT1689410E (pt) 2008-08-18
ES2307064T3 (es) 2008-11-16
PA8618401A1 (es) 2005-08-04
JP2007512279A (ja) 2007-05-17

Similar Documents

Publication Publication Date Title
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE458753T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE602004008069D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60108847D1 (de) Knollenförmige klappe und stent zur behandlung von gefässrückfluss
DE60022754D1 (de) Diagnose und behandlung von arrhythmien
ATE434444T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
EP1742675A4 (de) Behandlung von biomedizinischem abfall
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
DE60330693D1 (de) WuRMEBEHANDLUNGSVERFAHREN UND WuRMEBEHANDLUNGSVORRICHTUNG
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE60325353D1 (de) Behandlung von mukositis
EP1416957A4 (de) Behandlung von immunerkrankungen und b-zellen-erkrankungen
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
DE602004001134D1 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE602004014020D1 (de) Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
DE60315490D1 (de) Therapeutische behandlung
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1689410

Country of ref document: EP

REN Ceased due to non-payment of the annual fee